ReviewPostgraduate medical journal2006
Probiotics and inflammatory bowel diseases.
Review in Postgraduate medical journal, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 85 citations in OpenAlex.
- Enhancement of intestinal barrier function and alleviation of mycophenolic acid toxicity by a probiotic-conditioned mediumFrontiers in nutrition · 2026Article
- Article
- The Networked Interaction between Probiotics and Intestine in Health and Disease: A Promising Success Story.Microorganisms · 2024Review
- Roles of Short-Chain Fatty Acids in Inflammatory Bowel Disease.Nutrients · 2023Review
- Oral Administration ofMicroorganisms · 2023Article
- In Vitro Screening for Probiotic Properties ofNutrients · 2023Article
- Review
- Bile Acids and the Microbiome: Making Sense of This Dynamic Relationship in Their Role and Management in Crohn's Disease.Canadian journal of gastroenterology & hepatology · 2022Review
- Metformin Affects Gut Microbiota Composition and Diversity Associated with Amelioration of Dextran Sulfate Sodium-Induced Colitis in Mice.Frontiers in pharmacology · 2021Article
- Efficacy of Dietary Supplements in Inflammatory Bowel Disease and Related Autoimmune Diseases.Nutrients · 2020Review
- Synthetic Biology Approaches to Engineer Probiotics and Members of the Human Microbiota for Biomedical Applications.Annual review of biomedical engineering · 2018Review
- Probiotic Mixture Protects Dextran Sulfate Sodium-Induced Colitis by Altering Tight Junction Protein Expressions and Increasing Tregs.Mediators of inflammation · 2018Article
- Seasonal variation in onset and relapse of IBD and a model to predict the frequency of onset, relapse, and severity of IBD based on artificial neural network.International journal of colorectal disease · 2015Article
- Bifidobacteria grown on human milk oligosaccharides downregulate the expression of inflammation-related genes in Caco-2 cells.BMC microbiology · 2015Article
- Intestinal microbiota: The explosive mixture at the origin of inflammatory bowel disease?World journal of gastrointestinal pathophysiology · 2014Review
- Biological pathways involved in the development of inflammatory bowel disease.Wiener klinische Wochenschrift · 2014Review
- A Probiotic Preparation Duolac-Gold Ameliorates Dextran Sulphate Sodium-induced Mouse Colitis by Downregulating the Expression of IL-6.Toxicological research · 2014Article
- Central role of the gut epithelial barrier in the pathogenesis of chronic intestinal inflammation: lessons learned from animal models and human genetics.Frontiers in immunology · 2013Review
- Novel xylan-controlled delivery of therapeutic proteins to inflamed colon by the human anaerobic commensal bacterium.Annals of the Royal College of Surgeons of England · 2013Article
- Clinical use and mechanisms of infliximab treatment on inflammatory bowel disease: a recent update.BioMed research international · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Enteric microflora profiles vary considerably between active inflammatory bowel diseases (IBD) and healthy conditions. Intestinal microflora may partake in the pathogenesis of IBD by one or some ways: specific pathogenic infection induces abnormal intestinal mucosal inflammation; aberrant microflora components trigger the onset of IBD; abnormal host immune response loses normal immune tolerance to luminal components; luminal antigens permeate through the defective mucosal barrier into mucosal lamina propria and induce abnormal inflammatory response. Preliminary studies suggest that administration of probiotics may be benefit for experimental colitis and clinical trials for IBD. Researches have been studying the function of probiotics. Introduction of probiotics can balance the aberrant enteric microflora in IBD patients, and reinforce the various lines of intestinal defence by inhibiting microbial pathogens growth, increasing intestinal epithelial tight junction and permeability, modulating immune response of intestinal epithelia and mucosal immune cells, secreting antimicrobial products, decomposing luminal pathogenic antigens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.